17 apr: FOCUS: Food Processors To Benefit From Cheaper Grain Prices
17 apr: UPDATE: Marathon Oil: Angola's Block 31 To Start Product..
17-04-2012 21:04:00

2nd UPDATE:Top Court Sides With Generic Drug Makers In Tactics Case

Relateret indhold
12:38 - 
Novo: Tresiba giver bedre blosukkerregulering til børn ..
15 sep - 
Aktier/middag: TDC lægger sig i bunden af svagt faldend..
15 sep - 
Aktier/åbning: Tv-køb sender TDC til tælling
Relateret debat
16:12 - 
Bare se kurven de sidste 20 år bagud.   Inte..
16:10 - 
Ja, diabetes patienterne bliver yngre og yngre. Det med..
14:10 - 
En artikel om sukkersyge problemet i Kina. Godt vi leve..

--Justices give generics new legal tool against brand rivals

--Sun unit wins case, calls ruling important for generic drug makers

--Case involved Novo Nordisk patent for diabetes drug Prandin

(Updates with comment from Novo in 12th paragraph, additional background.)

By Brent Kendall

Of DOW JONES NEWSWIRES

WASHINGTON -(Dow Jones)- The U.S. Supreme Court handed a victory to generic drug companies Tuesday, ruling they can file certain legal counterclaims against brand-drug companies in an effort to get their cheaper copycat medicines on the market.

The court, in an opinion written by Justice Elena Kagan, ruled unanimously that generic drug makers should be allowed to challenge the way brand-name manufacturers describe their patents to the Food and Drug Administration.

The decision overturned an appeals court ruling that said generic makers can't bring those legal claims against brand rivals.

The generics argued that their brand rivals, if left unchecked, can describe their patents broadly in FDA submissions as a way to shut out possible generic competition, even for unpatented uses of a drug. The Obama administration supported those arguments.

Brand drug companies said allowing the counterclaims could lead to costly litigation and undermine patent protection for innovative drugs that are costly to develop.

The controversy arises when the FDA considers a drug maker's application to market a generic drug. As part of that process, the agency considers whether the proposed generic will infringe a branded drug's patents. To determine infringement, the FDA relies on use codes submitted by brand companies that describe the scope of their patents. The agency does not independently verify the accuracy of companies' patent submissions.

As Kagan noted, "the breadth of the use code may make the difference between approval and denial of a generic company's application."

At issue was an appeal by Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries Ltd. (524715.BY), which is seeking to introduce a generic version of Novo Nordisk A/S's (NVO, NOVO-B.KO) diabetes drug Prandin.

One Novo Nordisk patent on the drug compound has expired, but the company holds a second patent, which doesn't expire until 2018, that involves the use of the drug in combination with another medicine.

The FDA has approved three uses for the drug. Caraco wants to introduce a generic version for the uses that aren't patented. The company said it couldn't do so because Novo Nordisk's description of its patent to the FDA was so broad that it foreclosed the agency from approving a generic version of the drug.

A Sun representative called Tuesday's ruling "a very important victory" for the company and the generic industry as a whole.

Novo said its FDA submission is correct. "We are confident that further proceedings will show Caraco's challenge to the use code narrative is meritless," James Shehan, general counsel of Novo's U.S. subsidiary, said in a statement.

In a related dispute, the two companies are fighting over the validity of the Novo patent, which a Michigan federal judge invalidated last year. That case is on appeal.

The case is Caraco Pharmaceutical Laboratories v. Novo Nordisk, 10-844.

-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com

(END) Dow Jones Newswires

April 17, 2012 15:04 ET (19:04 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
11 sep
NOVO-B
Ja neb der er dog en meget stor forskel.   Da FDA skulle tage stilling til Treshiba havde produktet ..
5
14:10
NOVO-B
En artikel om sukkersyge problemet i Kina. Godt vi lever i et samfund hvor der er adgang til medicin..
2
15 sep
NOVO-B
sagt på Gumsenumse sprog, så er den nok brudt ud af noget cwh agtigt noget på ved imod et target omk..
2
12 sep
NVO
Og så synes det er rimelig imponerende al den stund at Novo er en hel del milliarder mere værd en Vo..
2
11 sep
NOVO-B
Godt at se en god aktuel debat her på EI.
2
11 sep
NOVO-B
Diabetes forsvinder ikke som sygdom, præcis af samme årsag som lykkejægere i aktiemarkedet ikke fors..
2
15 sep
NOVO-B
Hvis alle i Kina hopper på en gang, ja så kan vi vel mærke det her i københavn. Hvornår de hopper e..
1
15 sep
NOVO-B
Hvornår kommer det investeringsrelavante? Venter spændt.
1
12 sep
NVO
Nu er produktet jo kun anbefalet til godkendelse Det er ikke godkendt endnu. Man forventer en omsætn..
1
12 sep
NVO
Jeg vil da nok mene at slankeprodukter har været temmelig lukrativ gennem årene... og endda for en m..
1

Lundbeck: Eli Lilly og Astrazeneca på vej med Alzheimers-middel

16-09-2014 16:29:37
Eli Lilly og Astrazeneca har indgået et partnerskab for at udvikle en mulig behandling til Alzheimers sygdom, fortæller medicinalvirksomhederne i en fælles medd..

Novo: Tresiba giver bedre blosukkerregulering til børn og unge

16-09-2014 12:38:17
Novo Nordisks langtidsvirkende insulinprodukt Tresiba i kombination med Novolog kan give forbedret langsigtet blodsukkerregulering hos børn og unge med type 1-d..

Aktier/middag: TDC retter sig i kedeligt marked

16-09-2014 11:43:28
De røde tal er tirsdag i klar overvægt på fondsbørsen i København, hvor mange investorer har valgt at blive på sidelinjen for at afvente onsdagens rentemøde i U..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Mærsk/Macquarie: Løfter kursmål til 20.400 kr. fra 17.600 kr.
2
Aktier/tendens: TDC i fortsat fokus på "mellemdag"
3
UK/Danske: Skotsk "ja" med mulige konsekvenser
4
Torm/fmd: Udvanding af aktionærerne forventelig
5
Novo: Tresiba giver bedre blosukkerregulering til børn og unge

Relaterede aktiekurser

Novo Nordisk B A/S 272,80 -0,9% Fald i aktiekurs
Novo-Nordisk A/S 47,27 -1,0% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
16. september 2014 17:28:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140915.2 - EUROWEB6 - 2014-09-16 17:28:09 - 2014-09-16 17:28:09 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x